Department of Oncology, Center of Experimental and Clinical Oncology, AOU-Careggi, Florence University, Florence, Italy.
Anticancer Res. 2014 Feb;34(2):905-7.
Gastrointestinal stromal tumors are uncommon intra-abdominal tumors. In fewer than 5% of cases, they originate primarily from the mesentery, omentum or peritoneum and these extra-gastrointestinal stromal tumors tend to have characteristics similar to gastrointestinal stromal.
We report a case of extra-gastrointestinal stromal tumor in a 76-year-old male, Eastern Cooperative Oncology Group (ECOG) performance status of 2. Abdominal Computed Tomography (CT) showed multiple non-homogeneous confluent nodules at the level of the greater omentum and mesentery, involving the bladder and rectum, with additional peritoneal nodules in the upper abdomen. In March 2008, the patient started imatinib mesylate at 400 mg/day. Instrumental examinations showed progressive response until thoracic-abdominal CT in February 2012 which documented a complete response. Follow-up ended in October 2013. Treatment with imatinib, in addition to pathological response, provided clinical benefit, a progressive regression of symptoms and improved the patient's ECOG performance status from 2 to 0.
胃肠道间质瘤是一种罕见的腹腔内肿瘤。不到 5%的病例原发于肠系膜、大网膜或腹膜,这些胃肠道外间质瘤往往具有与胃肠道间质瘤相似的特征。
我们报告了一例 76 岁男性的胃肠道外间质瘤病例,东部肿瘤协作组(ECOG)体能状态为 2 分。腹部计算机断层扫描(CT)显示大网膜和肠系膜水平有多发性非均匀融合结节,累及膀胱和直肠,上腹部还有额外的腹膜结节。2008 年 3 月,患者开始每天服用 400mg 甲磺酸伊马替尼。仪器检查显示持续应答,直至 2012 年 2 月的胸腹部 CT 显示完全应答。随访于 2013 年 10 月结束。伊马替尼治疗除了病理性反应外,还提供了临床益处,症状逐渐消退,患者的 ECOG 体能状态从 2 分提高到 0 分。